{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:26:50Z","timestamp":1765369610703,"version":"3.46.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.vaccine.2025.127952","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:16:52Z","timestamp":1763637412000},"page":"127952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Population-based serosurveys for SARS-CoV-2 transmission 2021\u20132022, Massachusetts USA"],"prefix":"10.1016","volume":"69","author":[{"given":"Estee Y.","family":"Cramer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustine O.","family":"Dada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shauna","family":"Onofrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Pearlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cluverius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Loveland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Hatch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Melnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Lover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monina R.","family":"Klevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2025.127952_bb0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang","year":"2022","journal-title":"Clin Rev Allergy Immunol [Internet]"},{"key":"10.1016\/j.vaccine.2025.127952_bb0010","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) Variant \u2014 United States, December 1\u20138, 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 Dec 17 [cited 2023 Nov 19];70(50):1731\u20134. Available from: http:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7050e1.htm?s_cid=mm7050e1_w.","DOI":"10.15585\/mmwr.mm7050e1"},{"issue":"7942","key":"10.1016\/j.vaccine.2025.127952_bb0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-022-05522-2","article-title":"The WHO estimates of excess mortality associated with the COVID-19 pandemic","volume":"613","author":"Msemburi","year":"2023","journal-title":"Nature [Internet]"},{"key":"10.1016\/j.vaccine.2025.127952_bb0020","unstructured":"Archive of COVID-19 cases (2020-2021). Reports from the Massachusetts Department of Public Health 2020\u20132021 [Internet]. Available from: https:\/\/www.mass.gov\/info-details\/archive-of-covid-19-cases-2020-2021#june-2021-."},{"key":"10.1016\/j.vaccine.2025.127952_bb0025","unstructured":"Johns Hopkins University. Massachusetts\u2013COVID-19 Overview. [Internet]. [cited 2025 Oct 31]. Available from: https:\/\/coronavirus.jhu.edu\/region\/us\/massachusetts."},{"year":"2020","series-title":"First Massachusetts coronavirus vaccines arrive at Boston Medical Center","author":"Dwinell","key":"10.1016\/j.vaccine.2025.127952_bb0030"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127952_bb0035","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2025.127952_bb0040","doi-asserted-by":"crossref","unstructured":"Beck EJ, Hsieh YH, Fernandez RE, Dashler G, Egbert ER, Truelove SA, et al. Differentiation of individuals previously infected with and vaccinated for SARS-CoV-2 in an inner-city emergency department. Tang YW, editor. J Clin Microbiol [Internet]. 2022 Mar 16 [cited 2025 Oct 31];60(3):e02390\u201321. Available from: https:\/\/doi.org\/10.1128\/jcm.02390-21.","DOI":"10.1128\/jcm.02390-21"},{"key":"10.1016\/j.vaccine.2025.127952_bb0045","doi-asserted-by":"crossref","unstructured":"Routledge I, Takahashi S, Epstein A, Hakim J, Janson O, Turcios K, et al. Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. Nat Commun [Internet]. 2022 May 4 [cited 2023 Nov 19];13(1):2451. Available from: https:\/\/www.nature.com\/articles\/s41467-022-30051-x.","DOI":"10.1038\/s41467-022-30051-x"},{"key":"10.1016\/j.vaccine.2025.127952_bb0050","doi-asserted-by":"crossref","unstructured":"Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet Infect Dis [Internet] 2020 July [cited 2023 Nov 19];20(7):758\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309920303224.","DOI":"10.1016\/S1473-3099(20)30322-4"},{"key":"10.1016\/j.vaccine.2025.127952_bb0055","doi-asserted-by":"crossref","unstructured":"Murhekar MV, Clapham H. COVID-19 serosurveys for public health decision making. Lancet Glob Health [Internet] 2021 May [cited 2023 Nov 19];9(5):e559\u201360. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214109X21000577.","DOI":"10.1016\/S2214-109X(21)00057-7"},{"key":"10.1016\/j.vaccine.2025.127952_bb0060","doi-asserted-by":"crossref","unstructured":"Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. eLife [Internet]. 2021 Mar 5 [cited 2023 Nov 19];10:e64206. Available from: https:\/\/elifesciences.org\/articles\/64206.","DOI":"10.7554\/eLife.64206"},{"key":"10.1016\/j.vaccine.2025.127952_bb0065","doi-asserted-by":"crossref","unstructured":"Snyder T, Ravenhurst J, Cramer EY, Reich NG, Balzer L, Alfandari D, et al. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July\u2013August 2020: a mail-based cross-sectional study. BMJ Open [Internet]. 2021 Aug [cited 2023 Nov 19]11(8)e051157. Available from: https:\/\/doi.org\/10.1136\/bmjopen-2021-051157.","DOI":"10.1136\/bmjopen-2021-051157"},{"key":"10.1016\/j.vaccine.2025.127952_bb0070","article-title":"Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA","author":"Matias","year":"2023","journal-title":"J. Racial and Ethnic Health Disparities 11, 110\u2013120 (202)"},{"key":"10.1016\/j.vaccine.2025.127952_bb0075","unstructured":"Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020\u2013May 2021. JAMA [Internet]. 2021 Oct 12 [cited 2023 Nov 19];326(14):1400. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2784013."},{"key":"10.1016\/j.vaccine.2025.127952_bb0080","doi-asserted-by":"crossref","unstructured":"Muehlenbein MP, Gassen J, Nowak TJ, Henderson AD, Weaver SP, Baker EJ. Waco COVID survey: a community-based SARS-CoV-2 serological surveillance study in Central Texas. J Community Health [Internet] 2023 Feb [cited 2023 Nov 19];48(1):104\u201312. Available from: https:\/\/doi.org\/10.1007\/s10900-022-01143-y.","DOI":"10.1007\/s10900-022-01143-y"},{"key":"10.1016\/j.vaccine.2025.127952_bb0085","doi-asserted-by":"crossref","unstructured":"Park S, Marcus GM, Olgin JE, Carton T, Hamad R, Pletcher MJ, et al. Unreported SARS-CoV-2 Home Testing and Test Positivity. JAMA Netw Open [Internet]. 2023 Jan 25 [cited 2024 Jan 3];6(1):e2252684. Available from: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800732.","DOI":"10.1001\/jamanetworkopen.2022.52684"},{"key":"10.1016\/j.vaccine.2025.127952_bb0090","unstructured":"Data Axle. Reach your ideal audience with Targeted B2B and B2C Lists [Internet]. Available from: https:\/\/www.data-axle.com\/info."},{"key":"10.1016\/j.vaccine.2025.127952_bb0095","unstructured":"Qualtrics. Qualtrics Computer Software. Version\u2013August 2021 [Internet]. Provo, Utah, USA; 2021. Available from: https:\/\/www.qualtrics.com."},{"year":"2021","series-title":"Salesforce computer software","author":"Salesforce.","key":"10.1016\/j.vaccine.2025.127952_bb0100"},{"key":"10.1016\/j.vaccine.2025.127952_bb0105","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. Version 12.5.8. J Biomed Inform [Internet]. 2019 July [cited 2024 Jan 7];95:103208. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1532046419301261.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"10.1016\/j.vaccine.2025.127952_bb0110","article-title":"Development and implementation of dried blood spot-based COVID-19 serological assays for epidemiologic studies","author":"Wong","year":"2022","journal-title":"Microbiol Spectr [Internet]"},{"key":"10.1016\/j.vaccine.2025.127952_bb0115","doi-asserted-by":"crossref","unstructured":"Weisser H, Steinhagen K, H\u00f6cker R, Borchardt-Loh\u00f6lter V, Anvari \u00d6, Kern PM. Evaluation of dried blood spots as alternative sampling material for serological detection of anti-SARS-CoV-2 antibodies using established ELISAs. Clin Chem Lab Med CCLM [Internet]. 2021 Apr 27 [cited 2025 Oct 31];59(5):979\u201385. Available from: https:\/\/doi.org\/10.1515\/cclm-2020-1436\/html.","DOI":"10.1515\/cclm-2020-1436"},{"key":"10.1016\/j.vaccine.2025.127952_bb0120","doi-asserted-by":"crossref","unstructured":"Turgeon CT, Sanders KA, Granger D, Nett SL, Hilgart H, Matern D, et al. Detection of SARS-CoV-2 IgG antibodies in dried blood spots. Diagn Microbiol Infect Dis [Internet]. 2021 Sept [cited 2025 Oct 31];101(1):115425. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889321001188.","DOI":"10.1016\/j.diagmicrobio.2021.115425"},{"key":"10.1016\/j.vaccine.2025.127952_bb0125","doi-asserted-by":"crossref","unstructured":"Schuh AJ, Satheshkumar PS, Dietz S, Bull-Otterson L, Charles M, Edens C, et al. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. Medina RA, editor. Microbiol Spectr [Internet]. 2022 Aug 31 [cited 2025 Oct 31];10(4):e01247\u201322. Available from: https:\/\/doi.org\/10.1128\/spectrum.01247-22.","DOI":"10.1128\/spectrum.01247-22"},{"key":"10.1016\/j.vaccine.2025.127952_bb0130","doi-asserted-by":"crossref","unstructured":"Souiri A, Lemriss S, El Maliki B, Falahi H, El Fahime E, El Kabbaj S. SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization. Vaccines [Internet]. 2023 Mar 3 [cited 2025 Oct 31];11(3):590. Available from: https:\/\/www.mdpi.com\/2076-393X\/11\/3\/590.","DOI":"10.3390\/vaccines11030590"},{"key":"10.1016\/j.vaccine.2025.127952_bb0135","doi-asserted-by":"crossref","unstructured":"Hempel H, Page M, Kemp T, Semper A, Brooks T, Pinto LA. The importance of using WHO International Standards to harmonise SARS-CoV-2 serological assays. Lancet Microbe [Internet]. 2024 Mar [cited 2025 Oct 31];5(3):e301\u20135. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524723002586.","DOI":"10.1016\/S2666-5247(23)00258-6"},{"key":"10.1016\/j.vaccine.2025.127952_bb0140","unstructured":"IPUMS USA. U.S. CENSUS DATA FOR SOCIAL, ECONOMIC, AND HEALTH RESEARCH [Internet]. 2023. Available from: https:\/\/usa.ipums.org\/usa\/."},{"key":"10.1016\/j.vaccine.2025.127952_bb0150","doi-asserted-by":"crossref","unstructured":"McGreevy KM, Lipsitz SR, Linder JA, Rimm E, Hoel DG. Using median regression to obtain adjusted estimates of central tendency for skewed laboratory and epidemiologic data. Clin Chem [Internet] 2009 Jan 1 [cited 2024 Oct 25];55(1):165\u20139. Available from: https:\/\/academic.oup.com\/clinchem\/article\/55\/1\/165\/5581459.","DOI":"10.1373\/clinchem.2008.106260"},{"year":"2021","series-title":"A language and environment for statistical computing (version 4.1.2) [Computer software] R Foundation for Statistical Computing [Internet]","author":"R Core Team","key":"10.1016\/j.vaccine.2025.127952_bb0155"},{"key":"10.1016\/j.vaccine.2025.127952_bb0160","doi-asserted-by":"crossref","unstructured":"Feng W, Xiang Y, Wu L, Chen Z, Li Q, Chen J, et al. Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine. J Clin Lab Anal [Internet]. 2022 June [cited 2024 Jan 8];36(6):e24479. Available from: https:\/\/doi.org\/10.1002\/jcla.24479.","DOI":"10.1002\/jcla.24479"},{"key":"10.1016\/j.vaccine.2025.127952_bb0165","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Mu\u00f1oz AD, Kosik I, Holly J, Yewdell JW. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci Adv [Internet]. 2022 Aug 5 [cited 2024 Jan 8];8(31):eabp9770. Available from: https:\/\/doi.org\/10.1126\/sciadv.abp9770.","DOI":"10.1126\/sciadv.abp9770"},{"key":"10.1016\/j.vaccine.2025.127952_bb0170","doi-asserted-by":"crossref","unstructured":"Van Elslande J, Oyaert M, Lorent N, Vande Weygaerde Y, Van Pottelbergh G, Godderis L, et al. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagn Microbiol Infect Dis [Internet]. 2022 May [cited 2025 Oct 31];103(1):115659. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288932200027X.","DOI":"10.1016\/j.diagmicrobio.2022.115659"},{"key":"10.1016\/j.vaccine.2025.127952_bb0175","doi-asserted-by":"crossref","unstructured":"Krutikov M, Palmer T, Tut G, Fuller C, Azmi B, Giddings R, et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longev [Internet] 2022 Jan [cited 2025 Oct 31];3(1):e13\u201321. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666756821002828.","DOI":"10.1016\/S2666-7568(21)00282-8"},{"key":"10.1016\/j.vaccine.2025.127952_bb0180","doi-asserted-by":"crossref","unstructured":"Brli\u0107 PK, Pavleti\u0107 M, Lerga M, Krstanovi\u0107 F, Mate\u0161i\u0107 MP, Mikli\u0107 K, et al. SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. Viruses [Internet]. 2022 Sept 4 [cited 2025 Oct 31];14(9):1966. Available from: https:\/\/www.mdpi.com\/1999-4915\/14\/9\/1966.","DOI":"10.3390\/v14091966"},{"key":"10.1016\/j.vaccine.2025.127952_bb0185","doi-asserted-by":"crossref","unstructured":"Grebe E, Stone M, Spencer BR, Akinseye A, Wright DJ, Di Germanio C, et al. Detection of Nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors. Emerg Infect Dis [Internet] 2024 Aug [cited 2025 Oct 31];30(8):1621\u201330. Available from: https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/8\/24-0659_article.","DOI":"10.3201\/eid3008.240659"},{"key":"10.1016\/j.vaccine.2025.127952_bb0190","doi-asserted-by":"crossref","unstructured":"Owusu-Boaitey N, Russell TW, Meyerowitz-Katz G, Levin AT, Herrera-Esposito D. Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study. Eurosurveillance [Internet]. 2023 May 25 [cited 2024 Jan 7];28(21). Available from: https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.21.2200809.","DOI":"10.2807\/1560-7917.ES.2023.28.21.2200809"},{"key":"10.1016\/j.vaccine.2025.127952_bb0195","doi-asserted-by":"crossref","unstructured":"Khoury DS, Schlub TE, Cromer D, Steain M, Fong Y, Gilbert PB, et al. Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerg Infect Dis [Internet]. 2023 Feb [cited 2024 Feb 9];29(2):381\u20138. Available from: https:\/\/wwwnc.cdc.gov\/eid\/article\/29\/2\/22-1422_article.","DOI":"10.3201\/eid2902.221422"},{"key":"10.1016\/j.vaccine.2025.127952_bb0200","doi-asserted-by":"crossref","unstructured":"Nilles EJ, Paulino CT, De St Aubin M, Duke W, Jarolim P, Sanchez IM, et al. Tracking immune correlates of protection for emerging SARS-CoV-2 variants. Lancet Infect Dis [Internet]. 2023 Feb [cited 2025 Oct 31];23(2):153\u20134. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309923000014.","DOI":"10.1016\/S1473-3099(23)00001-4"},{"key":"10.1016\/j.vaccine.2025.127952_bb0205","doi-asserted-by":"crossref","unstructured":"Loesche M, Karlson EW, Talabi O, Zhou G, Boutin N, Atchley R, et al. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies. Emerg Infect Dis [Internet]. 2022 Sept [cited 2025 Oct 31];28(9):1859\u201362. Available from: https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/9\/22-0729_article.htm.","DOI":"10.3201\/eid2809.220729"},{"key":"10.1016\/j.vaccine.2025.127952_bb0210","doi-asserted-by":"crossref","unstructured":"Binder RA, Matta AM, Forconi CS, Oduor CI, Bedekar P, Patrone PN, et al. Minding the margins: Evaluating the impact of COVID-19 among Latinx and Black communities with optimal qualitative serological assessment tools. Egorov AI, editor. PLOS ONE [Internet]. 2024 July 25 [cited 2025 Oct 31];19(7):e0307568. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0307568.","DOI":"10.1371\/journal.pone.0307568"},{"key":"10.1016\/j.vaccine.2025.127952_bb0215","unstructured":"UMass Donahue Institute. Summary of U.S. Census Bureau's 2022 county characteristics estimates for Massachusetts counties [internet]. UMass Donahue Institute Economic and public policy research population estimates Program; 2023 Aug [cited 2025 Oct 31]. Available from: https:\/\/donahue.umass.edu\/documents\/UMDI_V2022_County_Characteristics_Estimates_Report_1.pdf."},{"key":"10.1016\/j.vaccine.2025.127952_bb0220","unstructured":"World Population Review. Review. Massachusetts Counties by Population (2025). [Internet]. World Population Review. [cited 2025 Oct 31]. Available from: https:\/\/worldpopulationreview.com\/us-counties\/massachusetts."},{"key":"10.1016\/j.vaccine.2025.127952_bb0225","unstructured":"USAFacts. Massachusetts Coronavirus Vaccination Progress. [Internet]. [cited 2025 Oct 31]. Available from: https:\/\/usafacts.org\/visualizations\/covid-vaccine-tracker-states\/state\/massachusetts\/."},{"key":"10.1016\/j.vaccine.2025.127952_bb0230","doi-asserted-by":"crossref","unstructured":"B\u00e1lint G, V\u00f6r\u00f6s-Horv\u00e1th B, Sz\u00e9chenyi A. Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther [Internet]. 2022 May 7 [cited 2025 Oct 31];7(1):151. Available from: https:\/\/www.nature.com\/articles\/s41392-022-01009-8.","DOI":"10.1038\/s41392-022-01009-8"},{"key":"10.1016\/j.vaccine.2025.127952_bb0235","doi-asserted-by":"crossref","unstructured":"Harrigan SP, Wilton J, Chong M, Abdia Y, Velasquez Garcia H, Rose C, et al. Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases. Clin Infect Dis [Internet]. 2023 Feb 8 [cited 2025 Oct 31];76(3):e18\u201325. Available from: https:\/\/academic.oup.com\/cid\/article\/76\/3\/e18\/6679248.","DOI":"10.1093\/cid\/ciac705"},{"key":"10.1016\/j.vaccine.2025.127952_bb0240","doi-asserted-by":"crossref","unstructured":"Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings \u2014 Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 Aug 6 [cited 2025 Oct 31];70(31):1059\u201362. Available from: http:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7031e2.htm?s_cid=mm7031e2_w.","DOI":"10.15585\/mmwr.mm7031e2"},{"key":"10.1016\/j.vaccine.2025.127952_bb0245","unstructured":"Mass Department of Public Health (DPH). Massachusetts Department of Public Health. Daily COVID-19 Vaccine Report \u2013 July 1, 2022. [Internet]. 2022 July [cited 2025 Oct 31]. Available from: https:\/\/www.mass.gov\/doc\/daily-covid-19-vaccine-report-july-1-2022\/download."},{"key":"10.1016\/j.vaccine.2025.127952_bb0250","unstructured":"Lumey T. survey: Analysis of Complex Survey Samples. R package version 4.2.1. [Internet]. 2023 [cited 2025 Oct 31]. Available from: https:\/\/CRAN.R-project.org\/package=survey."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T07:29:33Z","timestamp":1765351773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25012502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S0264410X25012502"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127952","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population-based serosurveys for SARS-CoV-2 transmission 2021\u20132022, Massachusetts USA","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127952"}}